Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ONCT Oncternal Therapeutics Inc

-0.44 (-4.55%)
Last Updated: 12:41:58
Delayed by 15 minutes


Draw Mode:

Volume 1,857
Bid Price 9.34
Ask Price 9.49
News -
Day High 9.85


52 Week Range


Day Low 9.2201
Company Name Stock Ticker Symbol Market Type
Oncternal Therapeutics Inc ONCT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.44 -4.55% 9.2201 12:41:58
Open Price Low Price High Price Close Price Prev Close
9.63 9.2201 9.85 9.6601
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
40 1,857 $ 9.56 $ 17,756 - 5.22 - 19.00
Last Trade Time Type Quantity Stock Price Currency
13:38:00 2 $ 9.48 USD

Oncternal Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
27.29M 2.96M - 1.49M -44.17M -14.92 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Oncternal Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ONCT Message Board. Create One! See More Posts on ONCT Message Board See More Message Board Posts

Historical ONCT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.529.858.529.226,3450.70018.22%
1 Month9.5110.408.379.338,576-0.2899-3.05%
3 Months7.0013.145.56569.14213,1312.2231.72%
6 Months6.5013.145.56567.87176,5692.7241.85%
1 Year18.1719.005.228.17287,239-8.95-49.26%
3 Years138.40211.205.2264.59562,334-129.18-93.34%
5 Years137.40211.205.2275.82683,896-128.18-93.29%

Oncternal Therapeutics Description

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Your Recent History

Delayed Upgrade Clock